title: MicroRNA-221 mediates the effects of PDGF-BB on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells.
abstract: The platelet-derived growth factor (PDGF) signaling pathway has been found to play important roles in the development and progression of human cancers by regulating the processes of cell proliferation, apoptosis, migration, invasion, metastasis, and the acquisition of the epithelial-mesenchymal transition (EMT) phenotype. Moreover, PDGF signaling has also been found to alter the expression profile of miRNAs, leading to the reversal of EMT phenotype. Although the role of miRNAs in cancer has been documented, there are very few studies documenting the cellular consequences of targeted re-expression of specific miRNAs. Therefore, we investigated whether the treatment of human pancreatic cancer cells with PDGF could alter the expression profile of miRNAs, and we also assessed the cellular consequences. Our study demonstrates that miR-221 is essential for the PDGF-mediated EMT phenotype, migration, and growth of pancreatic cancer cells. Down-regulation of TRPS1 by miR-221 is critical for PDGF-mediated acquisition of the EMT phenotype. Additionally, the PDGF-dependent increase in cell proliferation appears to be mediated by inhibition of a specific target of miR-221 and down-regulation of p27Kip1.
authors: Department of Hepatobiliopancreatic Surgery, West China Hospital, Sichuan University, Chengdu, PR China.
authors: Anping
authors: A
authors: Su
authors: Sirong
authors: S
authors: He
authors: Bole
authors: B
authors: Tian
authors: Weiming
authors: W
authors: Hu
authors: Zhaoda
authors: Z
authors: Zhang
mesh_terms: D000077214:Becaplermin; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics*; D049109:Cell Proliferation / Q000187:drug effects; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects* / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000378:metabolism; D010641:Phenotype; D020574:Proto-Oncogene Proteins c-sis / Q000378:metabolism / Q000494:pharmacology*; D034622:RNA Interference; D012097:Repressor Proteins; D015398:Signal Transduction; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism
chemical_list: D000077214:Becaplermin; D050760:Cyclin-Dependent Kinase Inhibitor p27; D004268:DNA-Binding Proteins; D035683:MicroRNAs; D020574:Proto-Oncogene Proteins c-sis; D012097:Repressor Proteins; D014157:Transcription Factors; C525709:MIR221, human; C108387:TRPS1 protein, human
references: Am J Pathol. 1999 Feb;154(2):313-23
references: 10027389
references: Arch Dermatol Res. 1999 Jul-Aug;291(7-8):413-8
references: 10482011
references: EMBO J. 2007 Aug 8;26(15):3699-708
references: 17627278
references: Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8
references: 16039986
references: Nat Rev Cancer. 2004 Dec;4(12):948-55
references: 15573116
references: Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):264-9
references: 20018759
references: Biochim Biophys Acta. 2010 Aug;1806(1):122-30
references: 20434526
references: Cancer Res. 2008 Apr 1;68(7):2391-9
references: 18381447
references: Br J Cancer. 2013 Feb 5;108(2):361-9
references: 23329235
references: Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1554-9
references: 14747654
references: Nucleic Acids Res. 2011 May;39(10):4035-47
references: 21266476
references: Int J Cancer. 1995 Sep 4;62(5):529-35
references: 7665222
references: Cancer Microenviron. 2010 Feb 23;3(1):137-47
references: 21209780
references: Cancer Res. 2006 Sep 1;66(17):8319-26
references: 16951136
references: J Biol Chem. 2009 Feb 6;284(6):3728-38
references: 19088079
references: Nucleic Acids Res. 2005 Nov 24;33(20):6566-78
references: 16314317
references: Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51
references: 18718806
references: Cancers (Basel). 2011 Feb 21;3(1):716-29
references: 21643534
references: Exp Hematol. 2008 Oct;36(10):1354-1369
references: 18657893
references: Trends Cell Biol. 2008 Aug;18(8):357-9
references: 18585040
references: Genes Dev. 2004 Apr 15;18(8):862-76
references: 15078817
references: J Biol Chem. 2007 Aug 10;282(32):23716-24
references: 17569667
references: J Clin Endocrinol Metab. 2008 May;93(5):1600-8
references: 18270258
references: Mol Cell Biol. 2002 Dec;22(24):8592-600
references: 12446778
references: Sci Signal. 2011 Jun 14;4(177):ra41
references: 21673316
references: J Natl Cancer Inst. 1981 Jun;66(6):1191-308
references: 7017215
references: Oncogene. 2008 Sep 25;27(43):5651-61
references: 18521080
references: J Clin Invest. 2006 Jun;116(6):1561-70
references: 16741576
references: Cancer Res. 2007 Jul 1;67(13):6092-9
references: 17616664
references: Stem Cells. 2009 Aug;27(8):1712-21
references: 19544444
references: Cancer Res. 2010 May 1;70(9):3606-17
references: 20388782
references: Trends Mol Med. 2006 Dec;12(12):580-7
references: 17071139